Condition 1: breast cancer. Condition 2: colon cancer. Condition 3: Rectal cancer. Condition 4: Gastric cancer. Condition 5: Esophageal cancer. Condition 6: Head & Neck cancer. Condition 7: Thalassemia beta minor. Malignant neoplasm of breast Malignant neoplasm of colon Malignant neoplasm of rectum Malignant neoplasm of stomach Malignant neoplasm of esophagus Malignant neoplasm of other and ill-defined sites Thalassemia minor
Conditions
Interventions
Intervention 1: Intervention group 1: Beta thalassemia patients receiving erythropoietin beta(CinnaPoietin
CinnaGen, Tehran, Iran) 150 IU/kg/day subcutaneously 3 days a week(Even days) for a minimum of 6 weeks and maximum of 6 months. Intervention 2: Control group 1: Thalassemia patients not receiving eryt
CinnaGen, Tehran, Iran) 150 IU/kg/day subcutaneously 3 days a week(Even days) for a minimum of 6 weeks and maximum of 6 months. Intervention 4: Control group 2: Patients without beta thalassemia not r
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Aged over 18 years old Metastatic cancer patients on first-line chemotherapy plan Patients with visceral(confirmed with CT scan or MRI) or/and bone(less than 5-confirmed with bone scintigraphy) metastases Initial serum hemoglobin less than 13 g/dL
Exclusion criteria
Exclusion criteria: Leukemia/Plasma cell dyscrasia Less than 3 months life expectancy Major and intermedia thalassemia based on hemoglobin electrophoresis Patients at risk for vascular thromboembolism(e.g. history of venous thromboembolism or ischemic stroke, patients with metallic prostheses in heart or vessels(excluding coronary stents after one year of placement) Taking drugs which effect on estrogen/progesterone receptor or any other drug that raises risk of thromboembolism during chemotherapy Pregnancy Uncontrolled high blood pressure(systolic BP over 160mmHg or diastolic BP over 95mmHg in three visits within a month despite treatment) A history of taking therapeutic radiopharmaceuticals in past three months A history of blood transfusion within three months before trial initiation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum hemoglobin level. Timepoint: Before study, with each chemotherapy session. Method of measurement: Electrical-Impedance Cell Counting.;Shortness of breath. Timepoint: Before study, with each chemotherapy session. Method of measurement: Subjective _ According to NYHA Classification of dyspnea. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDavoud Jahansouz
Babol University of Medical Sciences
Outcome results
None listed